BMAC Nerve Allograft Study

NCT ID: NCT03964129

Last Updated: 2020-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-22

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, multi-center, proof of principle, phase I human safety study evaluating the sequential treatments of the Avance Nerve Graft, a commercially available decellularized processed peripheral nerve allograft, with autologous Bone Marrow Aspirate Concentrate (BMAC), a source of stem cells, for the repair of peripheral nerve injuries up to 7 cm in length. The purpose of this study is to establish a knowledge product, evaluating the safety profile of the Avance Nerve Graft, followed by the application of BMAC to support further investment into the promising area of using stem cells in conjunction with scaffolds.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Nerve Injury Upper Limb

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Avance Nerve Graft with autologous BMAC

The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.

Group Type EXPERIMENTAL

Avance Nerve Graft with Autologous BMAC

Intervention Type PROCEDURE

The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avance Nerve Graft with Autologous BMAC

The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or non-pregnant female 18 to 74 years of age.
* Undergoing peripheral nerve exploration or grafting with allograft in the upper extremity.
* Subjects must be inpatients or scheduled for surgery at the time of study enrollment.
* Has nerve conduction block injuries to the ulnar, median, radial or musculocutaneous nerve of either upper extremities that is less than two years from injury.
* Be willing to undergo tension free end-to-end nerve graft coaptation on both the proximal and distal portion of the nerve gap with the Avance Nerve Graft.
* Be willing to have bone marrow harvested from own body, concentrated, and applied to the site of nerve injury following the insertion of the Avance Nerve Graft.
* Be willing to participate and able to comply with all aspects of the treatment and evaluation schedule over a 18-month duration.
* Capable of giving their own consent to participate in the study, and willing to sign and date an IRB-approved written informed consent prior to initiation of any study procedures.
* Nerve conduction injury affecting sensory and motor function or solely motor function in the upper extremity.
* Nerve gaps following resection, up to 7 cm, inclusive.

Exclusion Criteria

* Subjects with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus requiring regular insulin therapy.
* Subjects who are undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular system.
* History of neurodegenerative disease, neuropathy, or diabetic neuropathy.
* History of chronic ischemic condition of the upper extremity.
* Cognitive limitation or mental illness preventing informed consent.
* Nerve injuries \>2 years post initial injury.
* Any participant who at the discretion of the Investigator is not suitable for inclusion in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Walter Reed National Military Medical Center

FED

Sponsor Role collaborator

Curtis National Hand Center at MedStar Union Memorial Hospital

UNKNOWN

Sponsor Role collaborator

Cleveland Clinic Lerner Research Institute

UNKNOWN

Sponsor Role collaborator

Brooke Army Medical Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Julia AV Nuelle

Orthopaedic Hand and Microvascular Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Julia Nuelle, MD

Role: PRINCIPAL_INVESTIGATOR

Brooke Army Medical Center

Leon J Nesti, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Walter Reed National Military Medical Center

Kenneth Means, MD

Role: PRINCIPAL_INVESTIGATOR

Curtis Hand Center at MedStar Union Memorial Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Curtis National Hand Center at MedStar Union Memorial Hospital

Baltimore, Maryland, United States

Site Status

Walter Reed National Military Medical Center

Bethesda, Maryland, United States

Site Status

San Antonio Military Medical Center

Fort Sam Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Brooks DN, Weber RV, Chao JD, Rinker BD, Zoldos J, Robichaux MR, Ruggeri SB, Anderson KA, Bonatz EE, Wisotsky SM, Cho MS, Wilson C, Cooper EO, Ingari JV, Safa B, Parrett BM, Buncke GM. Processed nerve allografts for peripheral nerve reconstruction: a multicenter study of utilization and outcomes in sensory, mixed, and motor nerve reconstructions. Microsurgery. 2012 Jan;32(1):1-14. doi: 10.1002/micr.20975. Epub 2011 Nov 28.

Reference Type BACKGROUND
PMID: 22121093 (View on PubMed)

Berger A, Millesi H. Nerve grafting. Clin Orthop Relat Res. 1978 Jun;(133):49-55.

Reference Type BACKGROUND
PMID: 688717 (View on PubMed)

Brushart, T.M. (2011). Nerve Repair (Oxford University Press).

Reference Type BACKGROUND

Centeno CJ, Al-Sayegh H, Freeman MD, Smith J, Murrell WD, Bubnov R. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016 Aug;40(8):1755-1765. doi: 10.1007/s00264-016-3162-y. Epub 2016 Mar 30.

Reference Type BACKGROUND
PMID: 27026621 (View on PubMed)

Center for Biologics Evaluation and Research, C. for D. and R.H. Cellular & Gene Therapy Guidances - Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products: Draft Guidance.

Reference Type BACKGROUND

Chen CJ, Ou YC, Liao SL, Chen WY, Chen SY, Wu CW, Wang CC, Wang WY, Huang YS, Hsu SH. Transplantation of bone marrow stromal cells for peripheral nerve repair. Exp Neurol. 2007 Mar;204(1):443-53. doi: 10.1016/j.expneurol.2006.12.004. Epub 2007 Jan 12.

Reference Type BACKGROUND
PMID: 17222827 (View on PubMed)

Cho MS, Rinker BD, Weber RV, Chao JD, Ingari JV, Brooks D, Buncke GM. Functional outcome following nerve repair in the upper extremity using processed nerve allograft. J Hand Surg Am. 2012 Nov;37(11):2340-9. doi: 10.1016/j.jhsa.2012.08.028.

Reference Type BACKGROUND
PMID: 23101532 (View on PubMed)

Dezawa M, Takahashi I, Esaki M, Takano M, Sawada H. Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. Eur J Neurosci. 2001 Dec;14(11):1771-6. doi: 10.1046/j.0953-816x.2001.01814.x.

Reference Type BACKGROUND
PMID: 11860471 (View on PubMed)

Ding F, Wu J, Yang Y, Hu W, Zhu Q, Tang X, Liu J, Gu X. Use of tissue-engineered nerve grafts consisting of a chitosan/poly(lactic-co-glycolic acid)-based scaffold included with bone marrow mesenchymal cells for bridging 50-mm dog sciatic nerve gaps. Tissue Eng Part A. 2010 Dec;16(12):3779-90. doi: 10.1089/ten.TEA.2010.0299. Epub 2010 Sep 6.

Reference Type BACKGROUND
PMID: 20666610 (View on PubMed)

Ducic I, Fu R, Iorio ML. Innovative treatment of peripheral nerve injuries: combined reconstructive concepts. Ann Plast Surg. 2012 Feb;68(2):180-7. doi: 10.1097/SAP.0b013e3182361b23.

Reference Type BACKGROUND
PMID: 22270569 (View on PubMed)

Dvali L, Mackinnon S. Nerve repair, grafting, and nerve transfers. Clin Plast Surg. 2003 Apr;30(2):203-21. doi: 10.1016/s0094-1298(02)00096-2.

Reference Type BACKGROUND
PMID: 12737353 (View on PubMed)

Frykman, G., and Gramyk, K. (1991). Results of Nerve Grafting In: Gelberman R. Operative nerve repair and reconstruction. (JB Lippincott).

Reference Type BACKGROUND

Galanakos SP, Zoubos AB, Ignatiadis I, Papakostas I, Gerostathopoulos NE, Soucacos PN. Repair of complete nerve lacerations at the forearm: an outcome study using Rosen-Lundborg protocol. Microsurgery. 2011 May;31(4):253-62. doi: 10.1002/micr.20845. Epub 2010 Dec 3.

Reference Type BACKGROUND
PMID: 21557303 (View on PubMed)

Graham, James B., Xue, Qing-Shan, Neubauer, Debbie, and Muir, David (2009). A chondroitinase-treated, decellularized nerve allograft compares favorably to the cellular isograft in rat peripheral nerve repair. 2, 19-29

Reference Type BACKGROUND

Guo Y, Chen G, Tian G, Tapia C. Sensory recovery following decellularized nerve allograft transplantation for digital nerve repair. J Plast Surg Hand Surg. 2013 Dec;47(6):451-3. doi: 10.3109/2000656X.2013.778862. Epub 2013 Jul 15.

Reference Type BACKGROUND
PMID: 23848418 (View on PubMed)

Hegde V, Shonuga O, Ellis S, Fragomen A, Kennedy J, Kudryashov V, Lane JM. A prospective comparison of 3 approved systems for autologous bone marrow concentration demonstrated nonequivalency in progenitor cell number and concentration. J Orthop Trauma. 2014 Oct;28(10):591-8. doi: 10.1097/BOT.0000000000000113.

Reference Type BACKGROUND
PMID: 24694554 (View on PubMed)

Hendrich C, Franz E, Waertel G, Krebs R, Jager M. Safety of autologous bone marrow aspiration concentrate transplantation: initial experiences in 101 patients. Orthop Rev (Pavia). 2009 Oct 10;1(2):e32. doi: 10.4081/or.2009.e32.

Reference Type BACKGROUND
PMID: 21808691 (View on PubMed)

Hernigou P, Homma Y, Flouzat-Lachaniette CH, Poignard A, Chevallier N, Rouard H. Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. J Bone Joint Surg Am. 2013 Dec 18;95(24):2215-21. doi: 10.2106/JBJS.M.00261.

Reference Type BACKGROUND
PMID: 24352775 (View on PubMed)

Hu N, Wu H, Xue C, Gong Y, Wu J, Xiao Z, Yang Y, Ding F, Gu X. Long-term outcome of the repair of 50 mm long median nerve defects in rhesus monkeys with marrow mesenchymal stem cells-containing, chitosan-based tissue engineered nerve grafts. Biomaterials. 2013 Jan;34(1):100-11. doi: 10.1016/j.biomaterials.2012.09.020. Epub 2012 Oct 11.

Reference Type BACKGROUND
PMID: 23063298 (View on PubMed)

Hu J, Zhu QT, Liu XL, Xu YB, Zhu JK. Repair of extended peripheral nerve lesions in rhesus monkeys using acellular allogenic nerve grafts implanted with autologous mesenchymal stem cells. Exp Neurol. 2007 Apr;204(2):658-66. doi: 10.1016/j.expneurol.2006.11.018. Epub 2007 Jan 10.

Reference Type BACKGROUND
PMID: 17316613 (View on PubMed)

IJpma FF, Nicolai JP, Meek MF. Sural nerve donor-site morbidity: thirty-four years of follow-up. Ann Plast Surg. 2006 Oct;57(4):391-5. doi: 10.1097/01.sap.0000221963.66229.b6.

Reference Type BACKGROUND
PMID: 16998330 (View on PubMed)

Isaacs J. Major peripheral nerve injuries. Hand Clin. 2013 Aug;29(3):371-82. doi: 10.1016/j.hcl.2013.04.006. Epub 2013 Jun 12.

Reference Type BACKGROUND
PMID: 23895717 (View on PubMed)

Jackson WM, Alexander PG, Bulken-Hoover JD, Vogler JA, Ji Y, McKay P, Nesti LJ, Tuan RS. Mesenchymal progenitor cells derived from traumatized muscle enhance neurite growth. J Tissue Eng Regen Med. 2013 Jun;7(6):443-51. doi: 10.1002/term.539. Epub 2012 May 3.

Reference Type BACKGROUND
PMID: 22552971 (View on PubMed)

Jager M, Jelinek EM, Wess KM, Scharfstadt A, Jacobson M, Kevy SV, Krauspe R. Bone marrow concentrate: a novel strategy for bone defect treatment. Curr Stem Cell Res Ther. 2009 Jan;4(1):34-43. doi: 10.2174/157488809787169039.

Reference Type BACKGROUND
PMID: 19149628 (View on PubMed)

Johnson PJ, Newton P, Hunter DA, Mackinnon SE. Nerve endoneurial microstructure facilitates uniform distribution of regenerative fibers: a post hoc comparison of midgraft nerve fiber densities. J Reconstr Microsurg. 2011 Feb;27(2):83-90. doi: 10.1055/s-0030-1267834. Epub 2010 Oct 13.

Reference Type BACKGROUND
PMID: 20945287 (View on PubMed)

Karabekmez FE, Duymaz A, Moran SL. Early clinical outcomes with the use of decellularized nerve allograft for repair of sensory defects within the hand. Hand (N Y). 2009 Sep;4(3):245-9. doi: 10.1007/s11552-009-9195-6. Epub 2009 May 2.

Reference Type BACKGROUND
PMID: 19412640 (View on PubMed)

Kragh, Kirby, J.M., and Ficke, J.R. Combat casualty care : lessons learned from OEF and OIF. Chapter 9: Extremity Injury. (2012) Editor-in-chief, Martha K. Lenhart; medical editor, Eric Savitsky; military editor, Brian Eastridge. Pgs. 393-484

Reference Type BACKGROUND

Lin MY, Manzano G, Gupta R. Nerve allografts and conduits in peripheral nerve repair. Hand Clin. 2013 Aug;29(3):331-48. doi: 10.1016/j.hcl.2013.04.003.

Reference Type BACKGROUND
PMID: 23895714 (View on PubMed)

Lohmeyer JA, Siemers F, Machens HG, Mailander P. The clinical use of artificial nerve conduits for digital nerve repair: a prospective cohort study and literature review. J Reconstr Microsurg. 2009 Jan;25(1):55-61. doi: 10.1055/s-0028-1103505. Epub 2008 Nov 26.

Reference Type BACKGROUND
PMID: 19037847 (View on PubMed)

Lundborg G. A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance. J Hand Surg Am. 2000 May;25(3):391-414. doi: 10.1053/jhsu.2000.4165.

Reference Type BACKGROUND
PMID: 10811744 (View on PubMed)

Lundborg G, Rosen B. The two-point discrimination test--time for a re-appraisal? J Hand Surg Br. 2004 Oct;29(5):418-22. doi: 10.1016/j.jhsb.2004.02.008.

Reference Type BACKGROUND
PMID: 15336741 (View on PubMed)

Mackinnon SE, Doolabh VB, Novak CB, Trulock EP. Clinical outcome following nerve allograft transplantation. Plast Reconstr Surg. 2001 May;107(6):1419-29. doi: 10.1097/00006534-200105000-00016.

Reference Type BACKGROUND
PMID: 11335811 (View on PubMed)

Meek MF, Coert JH, Robinson PH. Poor results after nerve grafting in the upper extremity: Quo vadis? Microsurgery. 2005;25(5):396-402. doi: 10.1002/micr.20137.

Reference Type BACKGROUND
PMID: 16032723 (View on PubMed)

Mimura T, Dezawa M, Kanno H, Sawada H, Yamamoto I. Peripheral nerve regeneration by transplantation of bone marrow stromal cell-derived Schwann cells in adult rats. J Neurosurg. 2004 Nov;101(5):806-12. doi: 10.3171/jns.2004.101.5.0806.

Reference Type BACKGROUND
PMID: 15540919 (View on PubMed)

Neubauer D, Graham JB, Muir D. Nerve grafts with various sensory and motor fiber compositions are equally effective for the repair of a mixed nerve defect. Exp Neurol. 2010 May;223(1):203-6. doi: 10.1016/j.expneurol.2009.08.013. Epub 2009 Aug 22.

Reference Type BACKGROUND
PMID: 19703442 (View on PubMed)

Noble J, Munro CA, Prasad VS, Midha R. Analysis of upper and lower extremity peripheral nerve injuries in a population of patients with multiple injuries. J Trauma. 1998 Jul;45(1):116-22. doi: 10.1097/00005373-199807000-00025.

Reference Type BACKGROUND
PMID: 9680023 (View on PubMed)

PRWeb. (2015). AxoGen Inc.'s Avance Nerve Graft Data Presented During Bese Clinical Papers Session at the 70th Annual Meeting of the American Society for Surgery of the Hand. Vocus, Inc. Sep. 10, 2015

Reference Type BACKGROUND

Reyes M, Verfaillie CM. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci. 2001 Jun;938:231-3; discussion 233-5. doi: 10.1111/j.1749-6632.2001.tb03593.x.

Reference Type BACKGROUND
PMID: 11458512 (View on PubMed)

Rinker B, Liau JY. A prospective randomized study comparing woven polyglycolic acid and autogenous vein conduits for reconstruction of digital nerve gaps. J Hand Surg Am. 2011 May;36(5):775-81. doi: 10.1016/j.jhsa.2011.01.030. Epub 2011 Apr 12.

Reference Type BACKGROUND
PMID: 21489720 (View on PubMed)

Siemionow M, Duggan W, Brzezicki G, Klimczak A, Grykien C, Gatherwright J, Nair D. Peripheral nerve defect repair with epineural tubes supported with bone marrow stromal cells: a preliminary report. Ann Plast Surg. 2011 Jul;67(1):73-84. doi: 10.1097/SAP.0b013e318223c2db.

Reference Type BACKGROUND
PMID: 21629045 (View on PubMed)

Taras JS, Amin N, Patel N, McCabe LA. Allograft reconstruction for digital nerve loss. J Hand Surg Am. 2013 Oct;38(10):1965-71. doi: 10.1016/j.jhsa.2013.07.008. Epub 2013 Aug 30.

Reference Type BACKGROUND
PMID: 23998191 (View on PubMed)

Wakao S, Hayashi T, Kitada M, Kohama M, Matsue D, Teramoto N, Ose T, Itokazu Y, Koshino K, Watabe H, Iida H, Takamoto T, Tabata Y, Dezawa M. Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration. Exp Neurol. 2010 Jun;223(2):537-47. doi: 10.1016/j.expneurol.2010.01.022. Epub 2010 Feb 11.

Reference Type BACKGROUND
PMID: 20153320 (View on PubMed)

Wang D, Liu XL, Zhu JK, Jiang L, Hu J, Zhang Y, Yang LM, Wang HG, Yi JH. Bridging small-gap peripheral nerve defects using acellular nerve allograft implanted with autologous bone marrow stromal cells in primates. Brain Res. 2008 Jan 10;1188:44-53. doi: 10.1016/j.brainres.2007.09.098. Epub 2007 Oct 18.

Reference Type BACKGROUND
PMID: 18061586 (View on PubMed)

Wang D, Liu XL, Zhu JK, Hu J, Jiang L, Zhang Y, Yang LM, Wang HG, Zhu QT, Yi JH, Xi TF. Repairing large radial nerve defects by acellular nerve allografts seeded with autologous bone marrow stromal cells in a monkey model. J Neurotrauma. 2010 Oct;27(10):1935-43. doi: 10.1089/neu.2010.1352.

Reference Type BACKGROUND
PMID: 20701436 (View on PubMed)

Wangensteen KJ, Kalliainen LK. Collagen tube conduits in peripheral nerve repair: a retrospective analysis. Hand (N Y). 2010 Sep;5(3):273-7. doi: 10.1007/s11552-009-9245-0. Epub 2009 Nov 24.

Reference Type BACKGROUND
PMID: 19937145 (View on PubMed)

Weber RA, Breidenbach WC, Brown RE, Jabaley ME, Mass DP. A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. Plast Reconstr Surg. 2000 Oct;106(5):1036-45; discussion 1046-8. doi: 10.1097/00006534-200010000-00013.

Reference Type BACKGROUND
PMID: 11039375 (View on PubMed)

Whitlock EL, Tuffaha SH, Luciano JP, Yan Y, Hunter DA, Magill CK, Moore AM, Tong AY, Mackinnon SE, Borschel GH. Processed allografts and type I collagen conduits for repair of peripheral nerve gaps. Muscle Nerve. 2009 Jun;39(6):787-99. doi: 10.1002/mus.21220.

Reference Type BACKGROUND
PMID: 19291791 (View on PubMed)

Zuniga JR. Sensory outcomes after reconstruction of lingual and inferior alveolar nerve discontinuities using processed nerve allograft--a case series. J Oral Maxillofac Surg. 2015 Apr;73(4):734-44. doi: 10.1016/j.joms.2014.10.030. Epub 2014 Nov 13.

Reference Type BACKGROUND
PMID: 25530279 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C.2017.074

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BM-MNCs for Lower Extremity Compartment Syndrome Injury
NCT03880656 ACTIVE_NOT_RECRUITING PHASE1
Autologous BMMNC Combined With HA Therapy for PAOD
NCT03214887 WITHDRAWN PHASE1/PHASE2
Cell Therapy in Chronic Limb Ischemia
NCT00533104 COMPLETED PHASE1/PHASE2
Treatment for Acute Spinal Cord Injury
NCT00695149 TERMINATED PHASE1/PHASE2